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patients with glomerulopathy
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Luiza de Andrade Braga Farias4 and Veralice Meireles Sales de Bruin1Abstract
Background: Despite a confirmed association between restless legs syndrome (RLS) and end-stage renal disease
(ESRD), there is no study on patients presenting with nephrotic syndrome (NS). To investigate the frequency of RLS
and poor quality sleep in NS-patients secondary to primary glomerulopathy with nearly normal glomerular filtration
rate (GFR) and its associated factors.
Methods: Patients with NS, defined as 24 h-urine protein greater than 3.5 g/1.73 m2 and hypoalbuminemia, (n = 99,
53 women) and a mean age of 36±11 years were studied. Age and sex-matched controls were used to compare
RLS and poor sleep quality prevalence. Standardized RLS questionnaire formulated by the International Restless
Legs Syndrome and Pittsburgh Sleep Quality Index (PSQI) were used.
Results: RLS was more frequent in NS-patients than in controls (22.8 vs. 4.0%, p = 0.01). Mean time since diagnosis
(52.2±34.1 vs. 28.6±22.5 months, p < 0.01) and 24 h-proteinuria (3.7±1.3 vs. 2.6±0.6 g/1.73 m2, p = 0.001) were
greater in NS-patients with RLS those not presenting RLS. Association between RLS with 24 h-proteinuria [OR = 2.31;
p = 0.007; 95% CI 1.87-2.89] and time since diagnosis [OR = 1.10; p = 0.003; CI = 1.02-1.39] were identified even after
controlling for age, GFR and diabetes. Sleep quality was poor in NS-patients than in controls (mean PSQI score 7.35±3.7
vs. 5.2±3.0, p = 0.003). In NS-patients, only RLS was associated with poor sleep quality (OR = 1.20; p = 0.004).
Conclusion: Poor quality sleep and RLS are frequent in NS-patients without ESRD. Pathophysiology of this association
must be further investigated.
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Glomerulopathy is a group of diseases that affect mainly
young adults between 20–40 years old [1]. Nephrotic
syndrome is one major presentation of glomerulopathies
and patients generally present with important edema,
lipid alterations, hypoalbuminemia, and possible loss of
renal function. Also, inflammation, oxidative stress and
endothelial dysfunction are associated-features of neph-
rotic syndrome [2].
The diagnosis of RLS is clinically based and requires
the presentation of all of the following four main symp-
toms: (1) an urge to move the legs, usually accompanied* Correspondence: alexandreliborio@yahoo.com.br
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reproduction in any medium, provided the orby unpleasant sensations; (2) precipitation of symptoms by
rest and inactivity; (3) symptom relief by movement; and
(4) worsening appearance in the evening or at night [3].
Restless legs syndrome, a sensory-motor neurological
disorder, can occur idiopathic or in association with
other clinical conditions [4]. It is a common disorder in
hemodialysis patients frequently leading to poor quality
sleep and daytime somnolence [5]. Restless legs syn-
drome is a common disorder in patients with advanced
chronic kidney disease (CKD) and hemodialysis patients
frequently leading to poor quality sleep and daytime
somnolence [5-7]. However, there is no study specifically
in patients with NS-associated primary glomerulopathy.
The aim of the present study was to estimate the preva-
lence of RLS and sleep quality in NS-patients due primary
glomerulopathy. Moreover, we intended to evaluate NS-
features associated with sleep disorders.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study design
This was a cross-sectional study of patients submitted to
renal biopsy due NS at a reference university hospital of
Brazil (Hospital Geral de Fortaleza) from October/2010
to December/2011. Demographic data, habits and comor-
bidities were recorded using specific questionnaires an-
swered concurrently in a face-to-face interview performed
by general physicians after adequate training. Nephrotic
syndrome was defined as 24 h-urine protein greater than
3.5 g/1.73 m2 associated with edema, hypoalbuminemia
(less than 3.0 g/dL) and lipid alteration (low-density lipo-
protein cholesterol – LDL > 130 mg/dL and/or triglycer-
ides > 300 mg/dL). Only patients presenting primary
minimal lesions (ML), focal segmental glomerulosclerosis
(FSGS), Membranous Nephropathy (MN), IgA nephropa-
thy (IgAN) and membranoproliferative glomerulonephritis
(MPGN) confirmed with kidney biopsy were included in
this study. Diagnosis was performed using light micros-
copy and immunofluorescence studies. Electron micros-
copy is not performed routinely at our service. Patients
with any evidence of secondary glomerulopathy or ad-
vanced CKD (GFR less than 15 mL/min/1.73 m2) were ex-
cluded. Age and sex-matched healthy subjects were
selected from the community as control group. The study
protocol was approved by the Research Ethics Committee
of Hospital Geral de Fortaleza and written informed con-
sent was obtained in all cases.
Measurements
Restless legs syndrome was investigated according to the
criteria of the International RLS Study Group (IRLSG)
[3]. This scale has been adapted for Brazilian patients
[8]. This questionnaire-based RLS diagnosis requires an-
swers consistently indicating presence of all four of the
basic RLS diagnostic criteria [9], i.e.: (1) A compelling
urge to move the legs usually accompanied by uncom-
fortable feelings in the legs that must be, (2) engendered
or exacerbated by rest (sitting or lying still), (3) relieved
by movement, and (4) worse in the evening and night
than the morning except for very severe cases when it
occurs at all times of the day. To exclude RLS “mimics”
[10], a unique neurologist evaluated patients with RLS
diagnosed by questionnaire. Also, patients under statin
therapy were routinely screened for rhabdomyolysis with
creatinine kinase measurement.
Sleep quality was evaluated by the Pittsburgh Sleep
Quality Index (PSQI) [11]. This scale has seven compo-
nents, each one dealing with a major aspect of sleep. In-
dividuals with a PSQI score > 6 were considered poor
sleepers.
All patients included in the study were being currently
treated with angiotensin-converting enzyme inhibitors
(ACE inhibitor) or AT1- receptor blocker (AT1R-blocker)in the absence of formal contraindications. In case of ster-
oid dependency or resistance, in ML and FSGS, the pri-
mary treatment was cyclosporine (CsA). MN was treated
primarily with CsA or steroids plus cyclophosphamide
according to baseline renal function. IgAN presenting with
nephrotic syndrome was treated preferentially with ste-
roids and MPGN patients received no immunosuppressive
treatment.Laboratory data and definitions
Medical records were retrieved to assess laboratory data
at the kidney biopsy time and the last evaluation prior to
study inclusion. Laboratory data included an assessment
of serum creatinine, total blood count, serum albumin,
total cholesterol, LDL cholesterol, High-density lipopro-
tein (HDL) cholesterol, triglycerides, ferritin, serum iron,
24 h-urine protein excretion rate (24 h-proteinuria) and
urinalysis. Serum creatinine was measured using a Jaffe
alkaline picrate assay. Serum albumin was measured
using bromocresol green colorimetric method. Total
cholesterol was measured using enzymatic method;
HDL-cholesterol by catalase inhibition; LDL-cholesterol
by Friedewald equation and triglycerides by enzymatic
method. Serum iron dosage was performed by ferrozine
reagent method and ferritin by turbidimetry.
Immunosuppressive treatment was considered only
when it was being used in the month anteceding the inter-
view. Edema was considered when it was present in the
last clinical evaluation. Hypertension was defined as blood
pressure above 140 × 90 mmHg at three or more medical
evaluation or a positive high blood pressure history under
regular treatment. Current smoker was considered when
patients had smoked at last three months. Hematuria was
considered as more than five red blood cells per high-
power microscopic field in two urine samples. Total re-
mission was considered when 24 h-proteinuria was less
than 500 mg; partial remission when there was a reduction
greater than 50% of initial 24 h-proteinuria and it was less
than 3.5 g/24 h/1.73 m2. Estimated GFR (eGFR) was cal-
culated using simplified MDRD equation.Statistical analysis
Descriptive statistics are expressed as mean ± SD or ab-
solute numbers, as appropriate. Student’s t-test was ap-
plied to compare continuous variables with equality of
variance and normal distribution. Categorical data were
compared using the chi-square or Fischer’s test when ap-
propriate. Logistic regression analysis was performed to
examine associations between variables and the presence
of RLS. We forced in the model factors associated with
RLS in previous studies (age, eGFR, ferritin levels and
diabetes). The statistical analysis was performed using
SPSS 19.0.
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From 142 patients submitted to renal biopsy during
study period, 116 had NS due primary glomerulopathy.
From these, 108 were invited to study participation andTable 1 Clinical and laboratory characteristics of all patients
All glomerulopathy













Diagnosed Cardiovascular Disease 4/99
Presence of edema 31













Serum Ferritin (μg/L) 56.7 ± 31.0
Last serum albumin (g/dL) 3.6±0.9
Last total cholesterol (mg/dL) 221.2±98.9
Last triglycerides (mg/dL) 146.2±58.3
Proteinuria at diagnosis (g/24 h/1.73 m2) 8.6±3.8





FSGS: focal and segmentar glomerulosclerosis; ML: minimal lesions; MN: membranou
Glomerulonephritis; CKD: Chronic Kidney Disease; ACE: angiotensin converting enzynine refused. Ninety-nine patients (53 female) were in-
cluded in this study. Subject characteristics are given in
Table 1. Mean age was 36.2±11.8 years. Main histological
diagnosis was ML/FSGS (n = 53) and MN (n = 29).and according RLS presence
Glomerulopathy
patients with
RLS (n = 18)
Glomerulopathy
patients with no


































s Nephropathy; IgAN: IgA nephropathy; MPGN: membranoproliferative
me; AT1R: angiotensin 1 receptor; PSQI: Pittsburgh Sleep Quality Index.
Table 2 Association between restless legs syndrome with
last 24 h-proteinuria and time of glomerulopathy
diagnosis after adjusting for age, estimated glomerular
filtration rate and diabetes







After adjusting for age, estimated glomerular filtration rate, serum ferritin and
presence of diabetes.
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nineteen received cyclosporine-based therapy. Thirty-
eight patients were in total remission, 26 were in partial
remission and 35 did not achieve remission. Significant
edema was present in 24 patients (25.5%) and 33 (35.1%)
had associated arterial hypertension. The mean eGFR
was 61±29 mL/min. None of the patients had ESRD
(eGFR < 15 mL/min) and the great majority (n = 79) had
eGFR higher than 60 mL/min. The mean time of glomeru-
lopathy diagnosis was 33.6±26 months.
RLS was detected in 18 individuals with glomeru-
lopathy and in 4 sex and age-matched controls with no-
previous history of renal disease (22.8 vs. 4.0%, p = 0.01).
After univariate analysis, patients with RLS had a greater
mean time of diagnosis (52±34 vs. 28±22 months, p <
0.01) and greater 24 h-proteinuria (3.7±1.3 vs. 2.6±0.6 g/
1.73 m2, p = 0.001) (Table 1). Even after forced adjust-
ment for age, eGFR and diabetes, an association between
RLS, time of diagnosis and 24 h-proteinuria was con-
firmed by logistic regression analysis odds ratio [OR =Figure 1 Study subjects’ quality of sleep components (sleep dimensio
sleep domain in control (white bar) or glomerulopathy group (black bar). #1.10; p = 0.003; 95% CI = 1.02-1.39], for each month since
diagnosis and 2.31 [95% CI 1.87-2.89], p = 0.007), for each
gram of 24 h-proteinuria, respectively – Table 2.
Patients with glomerulopathy had poor quality sleep
when compared to control group (mean PSQI score 7.35±
3.7 vs. 5.20±3.0, p = 0.003). Also, a PSQI score > 6 was
more frequent in patients than in controls (52.5 vs. 28.2%,
p < 0.001). Cases showed longer sleep latency (p = 0.003),
shorter sleep duration (p = 0.04), less sleep efficiency (p <
0.0001), more sleep disturbances (p < 0.0001), more use of
sedatives (p = 0.02) and more diurnal dysfunction (p <
0.0001) – Figure 1. Only RLS was associated with a poor
sleep quality in GP patients (PSQI > 6) – (OR = 1.20; p =
0.004; CI = 1.05-1.37) after adjustment for age, eGFR and
diabetes. There was no association between sleep quality
and 24 h-proteinuria or serum albumin levels.
Discussion
The most important result of this study is show, for the
first time, an increased frequency of RLS in NS-patients.
Moreover, these patients presented poor quality sleep
when compared with an age and sex-matched controls. In
view of recent advances in the RLS management, inclusive
with new proposed therapies [12,13], the early diagnosis is
important to reduce RLS impact on the patients.
Previous studies involving patients with chronic kidney
disease (CKD) have shown RLS as highly prevalent and
associated with anemia, GFR reduction, serum parathor-
mone and iron status [14,15]. Of importance, in our data,
79/99 of patients had an eGFR greater than 60 mL/min/
1.73 and none had ESRD. CKD-related complications such
as anemia, uremia, secondary hyperparathyroidism andns) as assessed by the PSQI. Graph represents mean points in each
p = 0.003, * p = 0.04, **p < 0.0001, ## p = 0.02.
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Also, it explains why serum ferritin, a known inflamma-
tory marker in CKD patients, was not increased in our
sample. This makes possible to evaluate the effects of
other clinical features of NS on RLS, such as, edema,
hypoalbuminemia, dyslipidemia and urine protein excre-
tion rate.
In this study, RLS was more than four times as likely
to be present in patients as in age and sex-matched con-
trols and these results are similar to those described in
hemodialysis patients (21%) in another study performed
in our region [7]. Overall, RLS is associated with aging
[17]: thus, the low age range in the present studied
population highlights the importance of RLS in associ-
ation with glomerulopathy. As expected due to the
higher eGFR in these patients, renal function was not as-
sociated with RLS. Time of diagnosis and last values of
24 h-proteinuria were the only independently associated
with RLS.
Twenty-four hours proteinuria is the main marker of
glomerulopathy activity. Generally, higher urine protein
excretion is associated with dyslipidemia, inflammation,
endothelial dysfunction and renal function decline [2].
All these findings are recognized factors associated with
RLS in patients with CKD [18,19]. Due absence of data
about inflammation and endothelial function, we cannot
speculate about the precise pathophysiological mecha-
nisms underling this association.
A large proportion of GP patients also reported poor
quality sleep. No clinical or laboratory parameter related
to nephrotic syndrome or its treatment was associated
with a PSQI > 6. In contrast, RLS was itself associated
with poor sleep quality and this highlights the import-
ance of diagnosing RLS. A recent study has been associ-
ated with RLS with cardiovascular disease, especially in
patients with CKD [20]. Considering GP are under in-
creased risk of vascular disease [21], mainly due progres-
sive decline in renal function, dyslipidemia, endothelial
dysfunction, it is important to diagnose and treat RLS in
this population.
Conclusion
This data is relevant because it describes for the first
time a high prevalence of RLS and poor sleep quality in
NS patients. Moreover, we have shown that urine pro-
tein excretion rate, the main marker of glomerulopathy
activity, is independently associated with RLS. Further
studies are warranted to investigate the mechanisms
underling this association.
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